Sales of Non-opioid Pain Patches Surge as Opioid Counterparts Face Intense Scrutiny; FMI Anticipates Logistical Delays Due to COVID-19 Pandemic

Future Market Insights (FMI), Dubai: The non-opioid pain patches market surpassed revenues worth US$ 3.1 Bn in 2019, witnessing a surge of 3.2% from that recorded in 2018. A detailed study by Future Market Insights (FMI) forecasts near- and long-term growth outlook of the non-opioid pain patches market. 2020 will be a challenging year for the market, as the COVID-19 outbreak has brought medical supplies on the spotlight.

Non-narcotic pain management solution has been gaining significant momentum, as it does not involve the risk of addiction as with opioid drug patches such as fentanyl patches, thereby offering tailwinds to the market growth. However, a headwind from factory closures and supply chain disruptions triggered by rapid spread of coronavirus across major regions has been showing fragility of access to non-opioid pain patches.

Lidocaine Patches to Capture Over 2/3rd of Total Revenue

Lidocaine patches continue to account for major share (69%) of manufacturers’ bottom lines, owing to their extended period of pain management with reduced risk for systemic side effects and drug interactions. These patches are also recommended as first-line therapy for the management of neuropathic pain in older patients.

Download Sample Copy with Table of Content: https://www.futuremarketinsights.com/reports/sample/rep-gb-11286

“Studies indicated that the initial presenting symptoms of COVID-19 infection, especially among elder patients with neuropathic pain as a comorbid, could be delayed or worsened by prescribed transdermal opioid patches. In such cases, demand for non-opioid pain patches is expected to move on an upward swing,” say the FMI analyst.

North America Takes the Lead, MEA to Witness Relatively Low Adoption

North America will continue to retain its dominance in the global non-opioid pain patches market, accounting for 58% of the total value in 2019. In North America, opioid-based patches for transdermal pain management are facing intense scrutiny during the COVID-19 pandemic, as they may induce potential immune suppression. With health care providers turning to better alternatives, growth prospects of the market are expected to remain high in the region.

Adoption of non-opioid pain patches in Middle East & Africa will continue to remain stagnant, due to low product awareness among patients. Moreover, a wide availability of low-cost, alternative treatments in low-income countries emerges as a key challenge for the market players.

As per the FMI study, the global non-opioid pain patches market is set to experience a CAGR of 4% over the forecast period (2019-2029). Gain access to FMI’s exclusive COVID-19 tracker here.

Source: Future Market Insights

Leave a comment

Your email address will not be published. Required fields are marked *